Literature DB >> 18992372

Recovery of deficient homologous recombination in Brca2-depleted mouse cells by wild-type Rad51 expression.

Shauna A Lee1, Céline Roques, Alissa C Magwood, Jean-Yves Masson, Mark D Baker.   

Abstract

The BRCA2 tumor suppressor is important in maintaining genomic stability. BRCA2 is proposed to control the availability, cellular localization and DNA binding activity of the central homologous recombination protein, RAD51, with loss of BRCA2 resulting in defective homologous recombination. Nevertheless, the roles of BRCA2 in regulating RAD51 and how other proteins implicated in RAD51 regulation, such as RAD52 and RAD54 function relative to BRCA2 is not known. In this study, we tested whether defective homologous recombination in Brca2-depleted mouse hybridoma cells could be rectified by expression of mouse Rad51 or the Rad51-interacting mouse proteins, Rad52 and Rad54. In the Brca2-depleted cells, defective homologous recombination can be restored by over-expression of wild-type mouse Rad51, but not mouse Rad52 or Rad54. Correction of the homologous recombination defect requires Rad51 ATPase activity. A sizeable fraction ( approximately 50%) of over-expressed wild-type Rad51 is nuclear localized. The restoration of homologous recombination in the presence of a low (i.e., non-functional) level of Brca2 by wild-type Rad51 over-expression is unexpected. We suggest that Rad51 may access the nuclear compartment in a Brca2-independent manner and when Rad51 is over-expressed, the normal requirement for Brca2 control over Rad51 function in homologous recombination is dispensable. Our studies support loss of Rad51 function as a critical underlying factor in the homologous recombination defect in the Brca2-depleted cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18992372     DOI: 10.1016/j.dnarep.2008.10.002

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  19 in total

1.  RAD51 mutants cause replication defects and chromosomal instability.

Authors:  Tae Moon Kim; Jun Ho Ko; Lingchuan Hu; Sung-A Kim; Alexander J R Bishop; Jan Vijg; Cristina Montagna; Paul Hasty
Journal:  Mol Cell Biol       Date:  2012-07-09       Impact factor: 4.272

2.  High levels of RAD51 perturb DNA replication elongation and cause unscheduled origin firing due to impaired CHK1 activation.

Authors:  Ann Christin Parplys; Jasna Irena Seelbach; Saskia Becker; Matthias Behr; Agnieszka Wrona; Camilla Jend; Wael Yassin Mansour; Simon Andreas Joosse; Horst-Werner Stuerzbecher; Helmut Pospiech; Cordula Petersen; Ekkehard Dikomey; Kerstin Borgmann
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Cellular redistribution of Rad51 in response to DNA damage: novel role for Rad51C.

Authors:  Otto S Gildemeister; Jay M Sage; Kendall L Knight
Journal:  J Biol Chem       Date:  2009-09-26       Impact factor: 5.157

4.  The RAD51-stimulatory compound RS-1 can exploit the RAD51 overexpression that exists in cancer cells and tumors.

Authors:  Jennifer M Mason; Hillary L Logan; Brian Budke; Megan Wu; Michal Pawlowski; Ralph R Weichselbaum; Alan P Kozikowski; Douglas K Bishop; Philip P Connell
Journal:  Cancer Res       Date:  2014-04-21       Impact factor: 12.701

5.  Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.

Authors:  Letizia Porcelli; Anna E Quatrale; Paola Mantuano; Maria G Leo; Nicola Silvestris; Jean F Rolland; Enza Carioggia; Marco Lioce; Angelo Paradiso; Amalia Azzariti
Journal:  Mol Oncol       Date:  2012-10-29       Impact factor: 6.603

6.  Nascent DNA synthesis during homologous recombination is synergistically promoted by the rad51 recombinase and DNA homology.

Authors:  Maureen M Mundia; Vatsal Desai; Alissa C Magwood; Mark D Baker
Journal:  Genetics       Date:  2014-02-28       Impact factor: 4.562

Review 7.  What is wrong with Fanconi anemia cells?

Authors:  Sharon B Cantor; Robert M Brosh
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

8.  Dynamic regulation of Rad51 by E2F1 and p53 in prostate cancer cells upon drug-induced DNA damage under hypoxia.

Authors:  Minghui Wu; Xue Wang; Natalie McGregor; Kenneth J Pienta; Jingsong Zhang
Journal:  Mol Pharmacol       Date:  2014-03-13       Impact factor: 4.436

Review 9.  PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.

Authors:  J-M Lee; J A Ledermann; E C Kohn
Journal:  Ann Oncol       Date:  2013-11-12       Impact factor: 32.976

Review 10.  Overexpression of RAD51 suppresses recombination defects: a possible mechanism to reverse genomic instability.

Authors:  David Schild; Claudia Wiese
Journal:  Nucleic Acids Res       Date:  2009-11-26       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.